David Teece

David J. Teece is an innovation scholar who has studied how markets for know-how and intellectual property function and is well known for a series of papers on capturing value from technology. He coined the term “appropriability regime” and has explored how the appropriability regime impacts business model choices, particularly in relation to technology licensing.

Prof. Teece is the director of the Tusher Initiative for the Management of Intellectual Capital at the University of California, Berkeley’s Haas School of Business. He has authored over 30 books and 200 scholarly papers, and has been cited almost 170,000 times, per Google Scholar.
Dr. Teece has been ranked as the world’s most-cited scholar in the combined field of business and management in an analysis of science-wide author citations published in PLOS Biology, a peer-reviewed journal. He is co-editor of the Palgrave Encyclopedia of Strategic Management.  Dr. Teece has received nine honorary doctorates and has been recognized by Royal Honors.

Securing the Future of the U.S. Biopharmaceutical Industry: The Most-Favored-Nation Paradox

By Sujai Shivakumar and Anne Pritchett The Trump administration is pursuing lowering prescription drug costs primarily to end what it describes as “global freeloading” and to ensure U.S. patients pay prices comparable to those in other developed nations. The administration argues that while the United States represents less than 5 percent
Read More

Universities, Patents, and the Future of U.S. Competitiveness

By Shruti Sharma and Chris Borges Universities are among the most powerful engines of U.S. innovation, transforming federal research investments into scientific discoveries that underpin economic growth, technological leadership, and national security. Current law, via the Bayh-Dole Act, allows universities to patent inventions and license them to private companies, with royalties
Read More

How Counterfeit Drugs Threaten U.S. Health and Innovation

By Anne Pritchett According to the Department of Homeland Security, counterfeit drugs “threaten national security and public safety directly when introduced into government and critical infrastructure supply chains, and indirectly if used to generate revenue for transnational criminal organizations.” Furthermore, counterfeit drugs harm pharmaceutical innovation by eroding profitability and investor
Read More